Salarius gets Nasdaq extension to regain listing compliance; milestones set for July/August 2025

Decoy Therapeutics Inc.

Nasdaq Hearings Panel granted extension to comply with Minimum Bid Price and Equity Standards.
Must regain compliance with Equity Standard (minimum $2.5M stockholders' equity) by early July 2025.
Must regain compliance with Minimum Bid Price (closing bid $1.00) by early August 2025.
Previously received delisting notices for non-compliance with both rules; hearing held June 3, 2025.
Failure to meet milestones may result in revocation of extension and delisting.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.